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MR imaging of therapy-induced changes
of bone marrow
Abstract MR imaging of bone mar-
row infiltration by hematologic
malignancies provides non-invasive
assays of bone marrow cellularity and
vascularity to supplement the infor-
mation provided by bone marrow
biopsies. This article will review the
MR imaging findings of bone marrow
infiltration by hematologic malignan-
cies with special focus on treatment
effects. MR imaging findings of the
bone marrow after radiation therapy
and chemotherapy will be described.
In addition, changes in bone marrow
microcirculation and metabolism after
anti-angiogenesis treatment will be
reviewed. Finally, new specific imag-
ing techniques for the depiction of
regulatory events that control blood
vessel growth and cell proliferation
will be discussed. Future develop-
ments are directed to yield com-
prehensive information about bone
marrow structure, function and
microenvironment.
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Introduction
Bone marrow is the fourth largest organ of the human body.
Its main function is the hematopoiesis, i.e., it provides the
body with erythrocytes, leukocytes and platelets in order to
maintain the oxygenation, immune function and auto-
restoration of the body.
MR imaging provides a non-invasive visualization of the
bone marrow and may be used to define its cellular or fat
content as well as its vascularity and metabolism. Treat-
ment effects due to irradiation, chemotherapy or other new
treatment regimens may change one or several of these
components, thereby causing local or generalized changes
in bone marrow signal intensity on MR images. This article
will provide an overview over such treatment-related bone
marrow signal changes on MR imaging. In order to
recognize these treatment effects, one has to be familiar
with the MR imaging features of the normal and non-
treated pathologic marrow. Thus, this article will first
provide a brief overview over MR imaging features of the
normal and non-treated pathologic marrow as a basis for
subsequent descriptions of the bone marrow after conser-
vative or new treatments.
Indications to study treatment effects
In patients with hematopoietic malignancies the diagnosis
of neoplastic bone marrow infiltration is crucial to
determine prognosis and to identify suitable treatment
protocols [1]. This diagnosis is usually obtained by iliac
crest biopsy, which is mandatory for staging and histo-
pathologic classification of the disease [2–4]. In non-
Hodgkin’s lymphoma (NHL) a neoplastic bone marrow
infiltration indicates the highest stage (stage four) accord-
ing to the Ann Arbor Classification. In cases of myeloma,
the extent of bone marrow infiltration may be associated
with any stage of the Salmon and Durie classification [2].
H. E. Daldrup-Link (*) . T. Henning .
T. M. Link
Department of Radiology,
University of California San Francisco,
505 Parnassus Ave.,
San Francisco, CA 94143-0628, USA
e-mail: daldrup@radiology.ucsf.edu
Tel.: +1-415-4764328
Fax: +1-415-4760616In both instances, iliac crest biopsy may be false negative
when the bone marrow infiltration is focal rather than
diffuse [3, 4].
The role of MR imaging for the depiction of bone
marrow infiltration by hematologic malignancies is con-
troversial and depends on the type, stage and clinical
course of the malignancy. For patients with multiple
myeloma, MR has been established in some centers as an
integrative technique for staging and treatment monitoring,
since it proved to be highly sensitive for the detection of
bone marrow infiltrates and provided important additional
information to conventional bone surveys. In several
studies, MR showed a higher sensitivity than conventional
bone surveys and bone scintigraphy for the detection of
focal bone marrow lesions [5, 6]. Thirty-three percent of
patients with myeloma were “understaged” based on the
skeletal survey when compared to MR [7]. And some MR
findings have been shown to have direct prognostic
relevance: In patients with stage 1 disease according to
Salmon and Durie, a pathologic bone marrow MR and
normal bone survey was associated with a worse prognosis
than a normal MR and normal bone survey [8, 9]. And in
patients with stage 3 disease according to Salmon and
Durie, a diffuse bone marrow infiltration, as shown on MR
images, was associated with a worse prognosis than a
multifocal bone marrow infiltration [10, 11].
For patients with Hodgkin’s lymphomas and high-grade
NHL, FDG-PET has been established as the imaging
modality of choice for staging and treatment monitoring
and MR imaging should only be considered in selected
cases with high risk of bone marrow involvement and
equivocal findings on PET or extracompartmental tumor
growth. Neither MR nor FDG-PET is meant to replace
marrow biopsy, because the histopathologic subtype of
lymphoma has to be defined, and because minimally
diffuse, microscopic marrow involvement can be false
negative with either imaging technique [12]. On the other
hand, routinely performed iliac crest biopsies cover only a
small portion of the entire bone marrow and also provide
potential false-negative findings [3, 4, 12]. Thus, in
selected patients with a high risk of bone marrow
involvement, MR imaging may contribute clinically
significant information. In a study by Hoane et al. in 98
patients with malignant lymphoma, up to one-third of the
patients evaluated with routine iliac crest biopsies had
occult marrow tumor detectable with MRI [12]. In
addition, patients with negative marrow biopsies but
pathologic MR were found to have a worse prognosis
than patients with negative marrow biopsies and normal
MR [13]. Thus, since the diagnosis of bone marrow
involvement affects treatment decisions and prognosis,
these authors concluded that optimal bone marrow
evaluation in such patients should include both biopsy
and MR [12]. Another valuable contribution of MR is its
capacity to detect soft-tissue paravertebral masses as well
as epidural masses and neural foramen invasion, which
may accompany vertebral disease. In case of clinical
symptoms such as unexplained back pain or new
neurological symptoms, MR is the modality of choice to
detect paravertebral and epidural masses, which may
accompany bone marrow infiltration of the spine.
For patients with leukemia, there is currently no role for
routine bone marrow evaluation with MR imaging, neither
before nor after therapy. Particular questions in these
patients that may be addressed by MR are the search for
biopsy sites in patients with suspected new or relapsed
disease, but negative bone marrow biopsy as well as the
diagnosis of treatment complications, such as treatment
induced bone marrow infarcts or avascular necroses, when
conventional radiographs are negative or equivocal [14].
In summary, dedicated MR imaging of the bone marrow
in patients with hematologic malignancies is currently
restricted to applications in patients with multiple myelo-
ma, selected patients with other malignant lymphomas with
a high risk of bone marrow infiltration and/or extracom-
partmental tumor growth as well as patients with potential
treatment complications. Additional patients with hemato-
logic malignancies may undergo MR imaging for evalua-
tions of other pathologies, outside the bone marrow. And
since the bone marrow is depicted on nearly any MR
examination throughout the body, the knowledge of the
normal and pathologic marrow of these patients before and
after therapy is crucial for the radiologist in order to
provide a comprehensive diagnosis. Such “secondary”
evaluations of the bone marrow may outperform above
mentioned primary indications in this patient population.
Technique
Standard techniques to depict the bone marrow at 1 T and
1.5 T clinical scanners comprise plain T1-weighted
spinecho (SE) or fast-SE (FSE) sequences as well as
short TI inversion recovery (STIR) sequences. The T1-
weighted,non-fat-saturatedspinecho(SE)orFSE sequences
are best suited to define the cellular content of the bone
marrow and should be included in any protocol for MR
imaging of the bone marrow. STIR sequences are useful
as a screening sequence to search for abnormalities in the
bone marrow, most of which appear with a very high
signal intensity on these sequences. There is some debate
about the optimal inversion time (TI) for depiction of the
bone marrow abnormalities with STIR sequences [15–
18]: Some authors prefer a TI that causes a suppression of
all normal structures and provides a maximal contrast
between normal (no signal) and pathologic (high signal)
tissues. Other authors prefer a TI, which is slightly higher
in order to provide some additional background signal of
normal tissues (low signal), and, thus, improved anatom-
ical information. The advantages of STIR sequences are
that they provide a very high tissue contrast and that they
are insensitive to magnetic field inhomogeneities. The
744disadvantages are that STIR sequences have a limited
signal-to-noise ratio and that the fat suppression technique
is non-specific: The signal from tissue or fluid with a T1
similar to that of fat will also be suppressed, for example,
mucoid tissue, hemorrhage, proteinaceous fluid, and
gadolinium [18].
Selective fat-suppressed T2-weighted images are an
alternative to STIR-images at high field MR scanners.
Selective fat saturation is lipid specific, usually provides a
higher signal-to-noise ratio than STIR sequences and does
not suppress gadolinium-based contrast agent (i.e., can be
added after contrast medium administration). However,
selective fat saturation is susceptible to magnetic field
inhomogeneities. To achieve reliable fat saturation, the
frequency of the frequency-selective saturation pulse must
equal the resonance frequency of lipid. Inhomogeneities of
the static magnetic field will shift the resonance frequen-
cies of both water and lipid, this discrepancy would result
in poor fat suppression or - even worse - saturation of the
water signal instead of the lipid signal. Static field
inhomogeneities inherent in magnet design are relatively
small in modern magnets and can be reduced by decreasing
the field of view, centering over the region of interest, and
autoshimming. However, substantial inhomogeneities can
be caused by local magnetic susceptibility differences such
as those found at air-bone interfaces or around foreign
bodies like metal or air collections [18]. Of note, T2-
weighted FSE sequences without fat saturation are
probably the worst sequences for evaluation of the bone
marrow since both lesions and normal fatty marrow appear
hyperintense on these sequences.
Other MR imaging techniques have been developed to
improve the detection and quantification of diffuse bone
marrow involvement. These techniques include chemical-
shift imaging, bulk T1 relaxation time measurement, and
hydrogen 1 spectroscopy [19]. All of these methods were
used to measure the fat content or the water/fat fraction
more accurately. However, these measurements have so far
not demonstrated clinical significance, and hence these
techniques are currently not used for routine imaging.
Diffusion-weighted MR imaging techniques have been
reported to be useful for the differentiation of neoplastic
marrow infiltration and pathologic vertebral fractures [20].
Recently, further advanced diffusion-weighted whole body
scans have been described for treatment monitoring of
patients with leukemia [21]. The technique relies on
selective excitation of the water resonance and generation
of image contrast that is dependent upon differential
nuclear relaxation times and self-diffusion coefficients.
Contrast-agent enhanced scans In most instances, the
administration of Gd-based contrast agents is not
necessary for evaluation of bone marrow disorders.
Administration of Gd-DTPA can be helpful to differen-
tiate cysts and tumors, to differentiate necrotic and viable
tumor tissue before a biopsy, in suspected osteomyelitis
or in equivocal cases of bone infarcts. If Gd-DTPA-
enhanced scans are performed, fat saturated T1-weighted
sequences should be used in order to suppress the fatty
components of the bone marrow with intrinsic high signal
intensity and, thus, to provide an optimal depiction of the
Gd-enhancement.
The diagnosis of lesion vascularization based on
comparisons between plain non-fat-saturated and fat-
saturated, Gd-enhanced T1-weighted sequences is no
problem, if the investigated focal lesion shows a marked
enhancement. However, it may be difficult to determine, if
a certain lesion shows minimal or no contrast enhancement
based on comparisons of plain non-fat-saturated and fat-
saturated Gd-enhanced sequences. In these cases, we
recommend to obtain additional Gd-enhanced non-fat-
saturated T1-weighted MR sequences with identical pulse
sequence parameters as the plain sequences. A subtraction
of pre and post sequences can then identify a presence or
absence of contrast enhancement of certain focal lesions,
listed above.
Additional dynamic, contrast enhanced scans after
administration of Gd-DTPA have been applied by some
investigators in order to generate estimates of the blood
volume of the normal or pathologic bone marrow before
and after treatment [22, 23]. Such dynamic contrast
enhanced MR studies with gadolinium chelates should be
performed with rapid acquisition techniques, producing
interscan intervals as short as possible, to best measure the
rapidly evolving distribution patterns of these small
molecular probes (<600 daltons). Although investigated
since 1993 [23], dynamic Gd-DTPA-enhanced MR studies
have not shown clinical significance so far. In addition to
bone marrow perfusion, the amount of contrast agent at any
time within the bone marrow depends on several additional
inter-related variables including microvessel permeability,
endothelial surface area, hydrostatic pressure, osmotic
pressure, diffusion, convective forces, interstitial pressure
and clearance. Clearly, contrast media kinetics in the bone
marrow is not a simple matter and shows a high
interindividual and intraindividual variability with respect
to the mentioned influencing factors [24–26]. This may be
one reason why it did not find wide clinical application to
date.
New, macromolecular contrast media (MMCM) may
provide more specific information on bone marrow blood
volume and sinus permeability, which may be more useful
to study treatment effects. Small molecular Gd-chelates can
only estimate the blood volume (immediate post-contrast
scans) and extracellular space (later post-contrast scans) of
the normal or abnormal bone marrow, because these small
molecules permeate readily and non-selectively across
normal and abnormal capillaries in the bone marrow.
MMCM can also estimate the blood volume based on
immediate post-contrast scans. In addition, MMCM are so
large that their diffusion across microvessels is affected by
the permeability of these vessels. This may be helpful for
745treatment monitoring of anti-angiogenesis drugs, which
specifically and readily decrease microvascular permeabil-
ity, but which have no immediate effect on the blood
volume. Thus, MMCM may be able to predict a response to
anti-angiogenic treatment before a subsequent arrest in
tumor vessel growth (decrease in blood volume) and before
clinical signs of response (laboratory parameters) are
apparent [27]. At this time, none of the MMCMs are yet
FDA approved, but several of these agents are currently in
advanced stages of development for applications in patients
(phase II and III clinical trials), such as MS-325/Vasovist
(Epix and Schering, approved in Europe), Gadomer-17
(Schering), SHU555C (Schering), Sinerem/Combidex
(Guerbet/Advanced Magnetics), B-22956/1 (Bracco) and
Code 7228 (Advanced Magnetics). In order to acquire
useful kinetic information from MMCM-enhanced studies,
a series of images spanning at least 20–30 minutes after
contrast medium administration, is required [27]. On the
other hand, since the transendothelial diffusion of MMCM
is a rather slow process, it is usually sufficient to acquire
MMCM-enhanced dynamic data with intervals of one to
two minutes or, for specific questions, even to obtain just
one delayed contrast enhanced scan. Applications of
potential clinical interest will be mentioned in the specific
sections below.
One new class of contrast agents, particularly note-
worthy with respect to bone marrow imaging, is the group
of ultra small superparamagnetic iron oxide particles
(USPIO). These particulate iron oxide contrast agents are
phagocytosed by macrophages in the normal bone marrow,
where they induce a T2-shortening effect. The principle is
similar to MR imaging of the liver with superparamagnetic
iron oxide particles (SPIO). However, SPIO, used for liver
imaging have a diameter of >50 nm, whereas USPIO used
for bone marrow imaging have a diameter of <50 nm.
USPIO particles are not taken up in neoplastic marrow
infiltrates, which do not contain macrophages [28–30].
Thus, USPIO may be used to differentiate hypercellular
normal and neoplastic marrow. After infusion of USPIO at
a dose of 2.6 mg/kg body weight, the normal marrow
shows a USPIO induced signal loss as opposed to focal
neoplastic infiltrates, which do not show any signal loss,
and, thus, stand out as bright lesions [17, 29, 31]. STIR- or
T2-weighted fat saturated sequences are best suited for
such USPIO-enhanced MR scans. Metz et al. found a
significantly increased number of detected focal bone
marrow lesions (<1 cm) in patients with lymphoprolifer-
ative disorders on these sequences after administration of
USPIO compared to non-enhanced scans [17]. The USPIO
Ferumoxtran-10 (Sinerem/Combidex, Guerbet / Advanced
Magnetics) is expected to become approved for clinical
applications in 2006 in Europe and has already shown its
ability to differentiate normal and pathologic hypercellular
marrow and to detect multifocal lesions within the bone
marrow [17, 31]. Other USPIOs, which are in different
stages of preclinical and clinical trials are SHU555C/
Resovist S (Schering), Code 7228 (Advanced Magnetics),
VSOP (Ferropharm) and Clariscan (Amersham/GE).
Future imaging developments are likely to generate
combined techniques that will maximize the information to
be extracted from the image. Tumor location, morphology
and function will be integrated. For example, both dynamic
contrast-enhanced MR imaging and MR spectroscopy can
be acquired in a single diagnostic session to define bone
marrow vascular and metabolic characteristics [32].
New developments for whole body MR imaging, such as
parallel imaging techniques, dedicated coils (Angio-
SURF), and the total imaging matrix (Siemens systems,
Avanto) may provide a “screening” of the whole red bone
marrow for tumor infiltration within a reasonable time.
Additional development is being directed towards
combined PET and MR imaging, either by retrospective
spatial registration of data from PET and MR images,
obtained on separate PET and MR machines or by
sequential data acquisitions on combined PET-MR scan-
ners [33, 34]. PET-MR imaging has been described as
superior, a least for some applications, compared to PET-
CT because of the improved intrinsic soft tissue contrast
and potential direct bone marrow depiction provided by
MR.
Normal bone marrow
The normal bone marrow undergoes age-related changes of
its cellular content with increasing age of the patient. In
adults, the normal bone marrow is characterized by a partial
or complete fatty conversion and low cellularity, which
leads to a relatively high signal intensity on plain T1-
weighted images and low signal intensity on STIR- or fat
saturated T2-weighted MRimages [35–38]. In children, the
normal bone marrow is highly cellular, which leads to a
low signal intensity on plain T1-weighted images and high
signal intensity on STIR- or fat saturated T2-weighted MR
images. With increasing age, a conversion from this highly
cellular marrow in children to fatty marrow in adults occurs
with a gradual increase of the bone marrow signal on T1-
weighted MR images and a gradual decline of the bone
marrow signal on STIR- or fat saturated T2-weighted MR
images over time. This conversion also follows a particular
distribution pattern within the skeleton: it starts in the
peripheral skeleton and progresses centrally [38]. Within
long bones, it first involves the epiphyses, then the
diaphyses and, finally, the metaphyses [38]. In the
vertebrae, it starts in the center, around the venous plexus,
and progresses peripherally [38]. In adults, the signal
intensity of the normal bone marrow is typically hyper-
intense to surrounding muscle and intervertebral disks on
T1-weighted MR images and hypointense to surrounding
muscle on STIR- or fat saturated T2-weighted MR images.
The knowledge of this pattern of conversion is useful to
differentiate normal cellular marrow from focal or diffuse
746neoplastic involvement and to recognize treatment effects
and tumor recurrence.
The enhancement of the normal bone marrow in healthy
persons after administration of standard small molecular
Gd-chelates can vary greatly (range 3-59%, mean 21%, SD
11%) and decreases with increasing age [26]. As a rule of
thumb, a signal Gd-enhancement of less than 40% on T1-
weighted MRimages wasreported to be normal in adults of
more than 40 years. However, this threshold is dependent
on the applied field strength and pulse sequence param-
eters. The relative enhancement of both normal and
abnormal marrow may be higher with new, more sensitive
pulse sequences [25]. Thus, each investigator should
establish the specific threshold for normal bone marrow
enhancement for the technique used at his particular MR
scanner and institution.
Pathologic bone marrow in hematologic malignancies
Neoplastic infiltration of the bone marrow in MR images
results in a replacement of the fatty converted marrow by
neoplastic cells, thereby increasing the cellular content of
the bone marrow, which results in a prolongation of T1-
and T2-relaxation times and subsequent decreased T1-
signal and increased T2-signal of the bone marrow. The
detection of neoplastic bone marrow infiltrations with MR
imaging depends on the quantity and distribution of
cellular infiltration.
The distribution of neoplastic bone marrow involvement
in patients with hematologic malignancies may be focal,
multifocal or diffuse. In patients with NHL, a focal or
multifocal involvement is more common than the diffuse
infiltration pattern. In patients with myeloma, an addi-
tional, typical “salt and pepper” or variegated distribution
may be observed, most frequently in stage I disease
according to Salmon and Durie. In patients with leukemia,
the bone marrow is usually involved in a diffuse fashion. A
multifocal involvement may be seen in a small proportion
of patients, particularly those with AML.
The detection of focal, multifocal and “salt and pepper”
or variegated infiltrations of the bone marrow in patients
with NHL is straight forward: The MR signal intensity of
focal bone marrow lesions is typically iso- or hypointense
to surrounding muscle and intervertebral disks on T1-
weighted MR images and hyperintense to surrounding
muscle on STIR- or fat saturated T2-weighted MR images.
Since these focal lesions are also associated with an
increased angiogenesis, they show an increased signal
enhancement compared to the surrounding bone marrow
on fat saturated T1-weighted MR images.
The detection of a diffuse bone marrow infiltration with
MR imaging is limited. Using standard MR scanners and
pulse sequences, an infiltration of the bone marrow with
more than 30% of neoplastic cells can be readily detected
by a diffusely decreased T1-signal and a diffusely
increased T2-signal [39]. An infiltration with less than
20% neoplastic cells cannot be distinguished from normal
marrow with standard MR pulse sequences. Several
authors reported a normal bone marrow MR signal in
patients with leukemia, in patients with early stages of bone
marrow invasion by lymphoproliferative diseases and even
in up to one-quarter of patients with stage III multiple
myeloma [40].
The administration of Gd-DTPA is not necessary for
staging of focal, multifocal and “salt and pepper” lesions,
which can be readily detected on plain MR scans. Dynamic
Gd-DTPA-enhanced MR scans documented repetitively an
increased blood volume (i.e., increased enhancement) of
neoplastic infiltrations compared to the normal bone
marrow [22, 23, 41]. As one would expect, the Gd-
enhancement was significantly higher in marked bone
marrow infiltrations than in mild or no infiltration (P<0.05)
and the enhancement was higher in lesions with high
vessel-density than in lesions with low vessel-density at
histology (P=0.01). In addition, a higher enhancement was
found in the presence of increased serum immunoglobulins
[42]. However, the Gd-DTPA enhancement of focal
neoplastic lesions has not shown additional clinically
significant information for staging purposes so far. In some
cases, Gd-administration may help to diagnose a diffuse
bone marrow infiltration. According to studies from
Staebler et al., a bone marrow signal intensity increase
exceeding 40% indicates a diffuse infiltration in adult
patients [43].
Irradiation
MR signal changes of the bone marrow during and after
irradiation are time and dose dependent: In the acute phase
(day 1–3 of irradiation), the bone marrow develops an
edema, which appears hypointense on T1-weighted MR
images and hyperintense on fat-saturated T2-weighted and
STIR-images. Contrast enhanced T1-weighted images
show a transiently increased enhancement of the bone
marrow during this phase. Subsequently (day 4–10), focal
T1-hyperintense and T2/STIR-hypointense areas of hem-
orrhage may occur. The bone marrow ultimately undergoes
a conversion to fatty marrow, which closely represents the
irradiation field and which appears very bright on T1-
weighted MR images (close to subcutaneous fat) and dark
on fat suppressed images (Fig. 1). Dependent on the
applied dose, this fatty transformation of the bone marrow
may be detected with MR imaging as early as 10–14 days
after therapeutic irradiation [44]. In other cases, the edema
may persist for weeks and a fatty conversion may only
become apparent months after the irradiation. This fatty
conversion is reversible after an irradiation of less than 30–
40 Gy and irreversible after an irradiation with more than
40 Gy. The time frame of reconversion after low dose
irradiation has not been specified so far and will be most
747likely highly variable with respect to potential additional
chemotherapy or GCSF-treatment, location and extend of
the affected anatomical area and age of the patient. Contrast
enhanced scans show a markedly decreased enhancement
of the fatty converted bone marrow.
In addition to these bone marrow signal changes in the
irradiation field, several authors also reported an additional
small, but measurable fatty conversion of the adjacent bone
marrow, outside of the irradiation field. The bone marrow
outside the irradiation field showed similar MR signal
intensity changes compared to the bone marrow within the
irradiation field, but to a much lower degree. Interpreta-
tions of these findings differ, the most appealing explana-
tion is a fatty conversion due to scatter irradiation [45, 46].
In children, irradiation may also cause impairment or
stop in skeletal maturation. Local irradiation may impair
the growth at the growth plate of the irradiated bone after
doses as little as 1.3 Gy [47]. In parallel to the above
described changes of the bone marrow in general, the
metaphyses and growth plates of the affected bones may
also show an edema on MR images initially, and, later, a
fatty conversion. The severity of impairment in bone
growth is dependent on the age of the patient at the time of
the irradiation and the administered dose. High doses may
lead to marked epimetaphyseal deformities. The affected
metaphyses of long bones may show horizontal or
longitudinal areas of signal loss of on T1- and T2-
weighted MR images, which resemble metaphyseal bands
and striations seen on conventional radiographs [47].
Irradiation of the spine may cause a scoliosis, which is
typically concave to the irradiation field, if only one side
of the spine was irradiated. In children, irradiation of the
whole spine may also result in a scoliosis. There is usually
an associated impairment of the growth of paraspinal
muscles as well as an impaired vertical growth of the
irradiated vertebrae. Depending on the applied dose, the
bone marrow of the vertebrae may undergo a usually
transient or (rarely) persistent fatty conversion and the
bone marrow in the peripheral skeleton may show a
compensatory hypercellularity.
Irradiation of the brain in children with acute leukemia
may result in growth arrest due to a deficiency in growth
hormone [47]. In these patients, the bone marrow usually
appears normal (in case of remission of the leukemia) on
MR images.
In children, irradiation of the proximal femur may cause
a slipped capital epiphysis [47]. This may be diagnosed
early on MRimages by an asymmetry andtypical widening
of the center or posteromedial region of the affected physis,
which is best seen on plain T1-weighted MR images. A
potential subsequent closure of the physis may be
diagnosed by sequential MRI, it typically develops from
the posterior portion anteriorly.
In adults, a short-term complication of local irradiation
may be the development of an “irradiation osteitis”, which
presents as a T1-hypointense, T2/STIR-hyperintense,
inhomogeneous edema on MR images in the irradiation
field and which shows a narrow zone of transition to the
adjacent, non-irradiated bone marrow. There is no
associated extraosseous soft tissue mass. The irradiation
osteitis may be associated with insufficiency fractures,
which may sometimes be better apparent on MR and
sometimes be better apparent on conventional radiographs.
Thus, imaging of a suspected irradiation osteitis should
always also include conventional radiographs of the
affected bone. Irradiation osteitis is rare in children [47].
Other short-term complications of irradiation are insuf-
ficiency fractures and avascular necroses (AVN) in the
irradiated bone. Insufficiency fractures are caused by
normal stress on weight-bearing bones with an irradia-
tion-induced decreased elastic resistance. Depending on
the acuteness of the fracture and the time interval after
irradiation, MR may show a more predominant edema or a
more predominant fatty conversion of the bone marrow.
The fracture line may be seen as a bright line on T2-
weighted and contrast enhanced T1-weighted MR images,
if it is surrounded by adjacent marrow edema (Fig. 2). AVN
is caused by an irradiation induced arteritis with fibrosis
and endothelial proliferation, blocked arterial inflow or
venous outflow, rise in intramedullary pressure, compro-
mised perfusion, and, finally, anoxia and death of bone
marrow cells. The MR imaging findings of AVN are
described in detail below.
As long-term complications, benign or malignant tumors
may occur after irradiation of the bone and bone marrow.
Osteochondromas are the most common tumors that may
Fig. 1 T1-weighted non-enhanced (a) and fat saturated contrast
enhanced (b) MR images after radiation therapy of a focal PNET
tumor infiltration in L 2. Note the fatty conversion of the bone
marrow in the irradiation field, L1 to L3, is only apparent on the
non-fat saturated non-enhanced MR image. The tumor in L2 shows
a mild Gd-enhancement after radiotherapy on contrast-enhanced
scans
748develop after total body irradiation (TBI). The irradiation
induced development of osteochondromas is inversely
related to the age of the patient at the time of the TBI. In
children, osteochondromas developed in about 6–18%
after TBI. The latency for the development of osteochon-
dromas after TBI is highly variable, but generally shorter
than the latency for the development of malignant tumors
[48]. On MR imaging, a continuity of the bone marrow
space with the lesion and a cartilage cap with a thickness of
not more than 3 mm are criteria to prove a benign
osteochondroma and to exclude a malignancy. Of note,
sarcomatous degeneration of an irradiation induced osteo-
chondroma is extremely rare, although incidental cases
have been reported [49]. Other benign bone tumors that
may develop after TBI are fibrous dysplasia and aneurys-
mal bone cysts [48].
Radiation-induced sarcoma is a rare late complication of
irradiation, which develops after a latency period of about
10 years in the previous irradiation field. Irradiation
induced sarcomas are not directly related to the local
radiation dose. Osteosarcomas, fibrosarcomas, malignant
fibrous histiocytomas, and other sarcomas may occur
[50, 51].
Cortisone treatment
Ischemic (avascular) necrosis is a well recognized compli-
cation of high dose cortisone treatment, seen in 1–10% of
patients in the initial treatment phase for leukemias or
lymphomas (Fig. 3). In addition, AVN occurs in 10% of
long-term survivors of bone marrow transplantation
(Fig. 4) who received high doses of steroids for the
prevention or treatment of graft-versus-host disease. AVN
has been also described after chemotherapy or irradiation
[47]. The apparently increasing prevalence of this compli-
cation may be due to increasing recognition based on
increasing use of MR imaging.
AVN is caused by vascular insufficiency, compromised
bone marrow perfusion, and, finally, anoxia and death of
bone marrow cells. Bones with end-arterial vascular supply
and poor collaterals are particularly prone to develop an
AVN, such as the femoral head, distal femur and proximal
tibia, proximal humeri, tali, scaphoid, and lunate bones.
Fig. 2 Coronal fat saturated T2-
weighted (3200/50 ms) (a), T1-
weighted (600/20 ms) (b) and
fat saturated T1-weighted
(600/20 ms) contrast-enhanced
(c) MR images of the knee of a
16 year-old patient who under-
went radiation therapy of the
lower femur and poplitea region.
Note fatty bone marrow con-
version and fracture lines at the
distal femur and proximal tibia
(arrows) consistent with irradia-
tion induced insufficiency
fractures
Fig. 3 Coronal fat saturated Spinecho (3200/46 ms) MR images of
the knee joint of a 13 year old boy with ALL after treatment with
high dose cortisone. There are multiple bone infarctions in the distal
femur and proximal tibia (arrows). MR studies were obtained
14months (a) and 28 months(b) after onset of treatment. Note that
the infarcts decrease in size
749Usually, the cartilage is not affected because it is nourished
by synovial fluid.
MRI is the most sensitive non-invasive method for
diagnosis of bone marrow infarction. Early forms of AVN
are characterized by a diffuse marrow edema. These T1-
hypointense and T2-hyperintense areas of edema may be
extensive and are non-specific in their MR appearance.
Potential causes, which may all be related to steroid
administration, are transient osteoporosis, osteomyelitis,
occult intraosseous fracture, and stress fracture. However,
in patients under high dose steroid treatment, these areas of
edema may represent an early stage of AVN and should be
considered a marker for potential progression to advanced
osteonecrosis. Therefore, careful examinations for osteo-
necrosis are necessary when bone marrow edema is seen is
these patients [52].
The classic MR appearance of advanced bone marrow
infarction is characterized by asegmental area of low signal
intensity in the subchondral bone on plain T1-weighted
pulse sequences, outlining a central area of marrow, which
may have variable signal intensities [53]. This crescentic,
ring-like well defined band of low signal intensity on T1-
weighted images is thought to represent the reactive
interface between the necrotic and reparative zones and
typically extends to the subchondral plate. On T2-weighted
images, this peripheral band classically appears hypoin-
tense with an adjacent hyperintense line - the “double line
sign”. The hyperintense inner zone represents hyperemic
granulation tissue, the hypointense outer zone represents
adjacent sclerotic bone. Though characteristic of AVN, this
sign is uncommon with the use of fast spin-echo sequences
with or without fat suppression and is not necessary for
diagnosis of the disease. There is no need to perform
conventional T2-weighted sequences to find this sign. On
STIR images, the band-like signal alterations of the bone
marrow (corresponding to the “inner zone”) usually appear
hyperintense.
Mitchell et al. described four stages of AVN based on
MR imaging findings [54]. The knowledge of these stages
may be helpful in the recognition of AVN. Class A lesions
had signal intensity characteristics analogous to those of
fat, i.e., high signal intensity on T1-weighted images and
intermediate signal intensity on T2-weighted images. Class
B lesions demonstrated signal intensity characteristics
similar to those of blood, i.e., high signal intensity on both
T1- and T2-weighted images. Class C lesions had signal
intensity properties similar to those of fluid, i.e., low signal
intensity on T1-weighted images and high signal intensity
on T2-weighted images. Class D lesions had signal
intensity properties similar to those of fibrous tissue,
i.e., low signal intensity on both T1- and T2-weighted
images (2). Class A signal intensity tended to reflect early
disease, and class D signal intensity tended to reflect late
disease. However, these stages may not occur in a
chronological order and did not show prognostic sig-
nificance [53, 54].
Fig. 4 Conventional radiograph
(a), sagittal T1-weighted
(600/20 ms) (b) and sagittal
STIR sequence (4000/70 ms, TI:
150 ms) (c) of the ankle in a
patient with a history of chronic
myeloid leukemia and bone
marrow transplantation, show-
ing multiple infarcts in the distal
tibia, the talus and the calcaneus
(arrows), which are not visual-
ized on the radiograph
750There is currently no established role for Gd-adminis-
tration in non-traumatic AVN.
Of note, in children, the proximal femur epiphyses may
show a residual, small subcortical rim of hematopoietic
marrow, which typically appears brighter than adjacent
muscles on plain T1-weighted MR images. This should not
be confused with the “double line sign” in early AVN,
which is characterized by a subcortical rim, which is iso- or
hypointense compared to surrounding muscle.
The percentage of the affected weight bearing surface
occupied by the AVN is the most reliable factor for
predicting outcome [52]. AVN that are entirely circum-
scribed, and that do not extend cranially to the cortical
subchondral margin, have a good outcome, independent of
the overall size of the AVN lesion. AVN that do extend to
the subchondral margin and are associated with epiphyseal
collapse are at risk to result in permanent disability.
AVN may present in an atypical fashion. For example
AVN of the spine typically involves a single vertebrae. The
MRI findings of a wedge-shaped lesion with fluid intensity
(hyperintense signal, like that of cerebrospinal fluid on T2-
weighted images) are characteristic for AVN. However,
AVN may involve two contiguous vertebrae and the
intervening disc and can then be confused with infective or
neoplastic processes [55].
Chemotherapy
Chemotherapy in patients with leukemia results in typical
signal changes of the bone marrow on MR images, which
reflect the underlying changes in the cellular composition
and vascularity of the bone marrow [56–58]. During the
first week of treatment, the bone marrow sinus becomes
dilated and hyperpermeable, leading to an edema. The
edematous bone marrow shows a low signal intensity on
plain T1-weighted MR images and a high signal intensity
on plain T2-weighted and STIR-images. This bone marrow
edema was reported to be more pronounced in patients with
AML than in patients with ALL, probably reflecting the
higher bone marrow toxicity of the chemotherapeutic drugs
applied for the treatment of AML (e.g., cytosine arabino-
side, which has a known high bone marrow toxicity) as
opposed to ALL. Subsequently, a marked decrease in bone
marrow cellularity and a fatty conversion of the bone
marrow develops, which is characterized by an increase in
T1- and T2-relaxation times, an increased signal intensity
on plain T1-weighted MR images (Fig. 5) and decreased
signal intensity on fat saturated T2-weighted and STIR-
images. After successful therapy, a normalization of the
MR signal occurs with regeneration of normal hematopoi-
etic cells in the bone marrow. This regeneration often
occurs in a multifocal pattern, i.e., within the fatty
converted marrow, multiple diffuse small foci of decreased
signal on T1-weighted images and increased signal on T2-
or STIR-images develop.
Hodgkin’s and non-Hodgkin’s lymphomas, low- and
high-grade lymphomas as well as distinct subgroups of
NHL differ markedly in response to treatment. In
Hodgkin’s lymphoma, a bone marrow infiltration at
diagnosis is rare and expected to resolve after treatment.
Patients with residual active bone marrow lesions need
additional, dedicated treatment. MR is non-specific in
differentiating residual viable from non-viable disease.
FDG-PET or (in equivocal cases) biopsy are preferable
diagnostic methods to answer these questions. There are
about 30 subtypes of NHL. About 30% of patients with
NHL develop a diffuse large B-cell lymphoma, an
aggressive B-cell lymphoma. About 20% of patients with
NHL develop a follicular lymphoma, an indolent B-cell
lymphoma [59]. About 6% of patients with NHL develop a
mantle cell lymphoma, an aggressive B-cell lymphoma that
is often widespread at diagnosis. Low-grade lymphomas
are considered incurable and are often followed by
“watchful waiting”. The aggressive high-grade lymphomas
are treated with aggressive therapy regimens, chemother-
Fig. 5 Coronal T1-weighted
spinecho (600/20 ms) images of
the pelvis before (a) and after
(b) chemotherapy for a fibro-
sarcoma of the pelvis (arrow).
Note a decrease of hematopoi-
etic bone marrow and an in-
creased fatty conversion in the
pelvis and bilateral proximal
femurs, while the tumor size
shrinks
751apy, irradiation, often a combination of both and/or
autologous bone marrow transplantation. Bone marrow
lesions in these patients are expected to change under
therapy on MR images. In general, MR images of patients
with Hodgkin’s lymphoma and NHL, including myeloma,
show a conversion from hypercellular, hypervascularized
to normocellular and less vascularized marrow after
chemotherapy. However, the “ideal” evolution from hy-
percellular to normocellular marrow may not occur in all
patients with malignant lymphomas. Rahmouni et al.
reported that the marrow often returned to normal after
treatment when the pattern was diffuse or variegated before
treatment [60]. But residual signal alterations of the bone
marrow have been also reported after the end of therapy,
particularly in patients with a focal pattern before treatment
(Fig. 6)[ 60]. A conversion of a diffuse to a focal MR
imaging pattern of marrow involvement, reduction, but not
disappearance in lesion size and number, and persistant
peripheral lesion enhancement on contrast-enhanced MR
images (Fig. 6) have been described in association with a
response to standard chemotherapy [58, 60]. In addition,
focal bone marrow lesions in patients with lymphoma may
show a persistent abnormal signal and/or a cystic or fatty
degeneration: A fatty or cystic conversion of focal lesions
has been reported as an indication for a response to
treatment (Fig. 7)[ 61]. Low signal intensity on post-
therapeutic T2-weighted images is usually associated with
fibrosis and rules out relapse. A persistent intermediate
hyperintense signal of focal bone marrow lesions on T2-
weighted MR images (non-cystic, non-fatty) has been
described in association with treatment induced necrosis
and inflammation and was found in both responding and
non-responding patients [60].
In patients with myeloma, new or progressive vertebral
compression fractures may occur as a complication of
treatment response in vertebrae that had extensive marrow
disease before treatment [58]. With response to treatment,
the tumor mass that had replaced the trabeculae, may
resolve and the unsupported vertebrae can collapse. An
increasing back pain in patients with myeloma after
treatment may be caused by such vertebral compression
fractures or tumor progression. Relapse and poor response
to treatment are well evaluated with MR imaging. In
patients with clinical relapse, new focal lesions, an increase
in the size of previously identified focal lesions or a change
from focal to diffuse infiltration may be seen. Additional
signs of tumor progression are increasing paraosseous soft
tissue masses or increased Gd-enhancement of focal
lesions after chemotherapy. A progress of focal to diffuse
bone marrow neoplasias may be sometimes more difficult
to assess, since a diffuse bone marrow infiltration may be
indistinguishable from reconverted hematopoietic marrow
after e.g., GCSF-treatment. As specified above, a new Gd-
enhancement of >40% or lack of USPIO uptake in a
hypercellular marrow may indicate a tumor progress or
recurrence in these cases.
A rare form of progression in myeloma under therapy is
leptomeningeal spread within the central nervous system,
reported in 18 out of a series of 1856 patients [62]. MR
findings of leptomeningeal enhancement in the brain or
spine helped to establish the diagnosis, which was
subsequently confirmed by cytologic analysis of cerebro-
spinal fluid. Myelofibrosis and amyloidosis can also
develop as a consequence of treatment in patients with
myeloma. Myelofibrosis can be suggested on MR studies
as a conversion of the entire bone marrow to diffuse
hypointensity on both T1-weighted and STIR images.
Amyloidosis can be seen as focal areas of hypointensity on
both T1-weighted and STIR images [63].
Perfusion studies using MR enhanced with standard
small molecular Gd-based contrast agents provide func-
tional information concerning the response of bone marrow
neoplasias to chemotherapy. Conventional cytotoxic drugs
have direct or indirect effects on angiogenesis and cause a
decrease in bone marrow contrast medium uptake within
weeks or months [22, 23, 41]. However, though these
techniques are clinically available for more than a decade,
perfusion studies are used infrequently or not at all in
clinical practice since the obtained functional changes in
bone marrow vascularity do not or only slightly precede the
Fig. 6 Sagittal T1-weighted Spinecho sequences (500– 700/15–
25 ms) with (a, c) and without (b, d) contrast before (a, b) and after
c, d) chemotherapy for lymphoma. Note decrease in size of the soft
tissue component after chemotherapy, yet still significant contrast
enhancement in the bone marrow
752obvious and readily apparent clinical parameters for
treatment response.
Treatment effects of various chemotherapeutic regimen
on the bone marrow in patients with leukemia and
lymphomas could be also detected with 31P MR spectros-
copy. A treatment induced change in tumor pH with an
alkaline shift was related temporally to increases in the
phosphodiester/beta-adenosine triphosphate ratio, and oc-
curred before alterations in tumor size were documented
[64]. And interestingly, changes in the 31P MR spectral
profile could not only be detected by direct investigations
of the bone marrow itself, but also by MR spectroscopy of
the serum of the patients. The 31P MR spectral profile of
the serum changed in responding patients to resemble that
of normal serum with typical, higher peak intensities as
compared to non-treated and non-responding patients [65].
Bone marrow reconversion after standard therapy
After successful cytotoxic therapy and/or irradiation, the
normal bone marrow may undergo a reconversion from
fatty to highly cellular hematopoietic marrow. This
reconversion occurs in a reverse fashion compared to the
conversion from hematopoietic marrow to fatty marrow,
described above, i.e., the reconversion progresses from the
central skeleton to the periphery. Within long bones, it
involves first the metaphyses and then the diaphyses. The
presence of cellular marrow within the epiphyses in an
adult patient with hematologic malignancies is always
suspicious for neoplastic infiltration, especially when the
rest of the bone marrow did not undergo a complete
reconversion. A reconversion of marrow within the
epiphyses is only rarely seen, usually in conjunction with
an extensive reconversion of the hematoietic marrow of the
whole bone.
In patients with lymphoma, the reconversion process
may be enhanced by administration of granulocyte colony
stimulating factor (GCSF), which activates the hematopoi-
etic marrow and decreases the period of aplasia after
chemotherapy [66]. The differentiation between this
reconverted, highly cellular normal hematopoietic marrow
andrecurrent tumor after chemotherapy is notpossible with
conventional MR techniques, since relaxation rates and
MR signal characteristics of highly cellular hematopoietic
and highly cellular neoplastic bone marrow are similar
[67]. Various investigators have addressed this problem,
but were not able to differentiate reconverted hypercellular
hematopoietic marrow and tumor infiltration using a
variety of pulse sequences, static post-contrast MR images,
and MR spectroscopy (Fig. 8)[ 66, 68].
Dynamic T1-weighted MR images after intravenous
bolus injection of standard small molecular Gd-chelates
may be helpful in the differentiation between normal
Fig. 7 Sagittal MR images of a patient with malignant lymphoma
and multifocal bone marrow infiltration. Sagittal STIR (a) and
contrast enhanced fat saturated T1-weighted fast SE sequences
(700/15–25 ms) were obtained before chemotherapy (a, b). Fat
saturated T2-weighted fast SE (4000/60 ms) ©, contrast enhanced
fat saturated T1-weighted fast SE sequences and non-contrast
enhanced T1-weighted SE sequences (600/20 ms) were obtained
after chemotherapy (c–e). After therapy, the areas of previous tumor
infiltration show a decreased signal on T2-weighted images, a
decreased contrast enhancement and fatty degeneration (arrows)
753hypercellular hematopoietic and neoplastic marrow. When
compared with red marrow, enhancement of abnormal
bone marrow occurred earlier, was steeper and did not last
as long in neoplastic bone marrow infiltrations [69–71].
However, in our experience, the Gd-enhancement of the
GCSF-treated, markedly hypercellular marrow and neo-
plastic marrow in patients with hematologic malignancies
shows considerable overlap and is of limited clinical value
for a definitive differentiation of these entities.
USPIO contrast agents may be more useful for such a
differentiation of reconverted marrow and tumor recur-
rence. The pathophysiologic basis for this is the distribu-
tion of RES cells in the bone marrow and their ability to
phagocytose exogenous iron oxides. After chemotherapy,
especially after GCSF treatment, the bone marrow
reconversion causes an increased quantity of all hemato-
poietic cell lines in the bone marrow, including RES cells
[72]. In bone marrow neoplasia, on the other hand, the
hematopoietic marrow is replaced by tumor cells and the
number of RES cells is substantially reduced [73]. Thus,
USPIO-enhanced MRI can differentiate these entities by
depicting iron oxide-targeted RES cells, which are present
in the reconverted hematopoietic marrow, but not present
or substantially reduced in focal or multifocal tumor
deposits [17, 29, 31]. Before USPIO administration, both,
the hypercellular hematopoietic and neoplastic marrow
appear of low signal intensity on plain T1-weighted MR
images and of high signal intensity on STIR and fat
saturated T2-weighted MR images (Fig. 8). After USPIO
administration, however, the normal marrow, which takes
up the USPIO, shows an iron oxide induced signal loss,
whereas focal neoplastic marrow infiltrates, which do not
take up the USPIO, stand out as bright lesions on STIR and
fat saturated T2-weighted MR images (Fig. 9)[ 17, 29, 31].
The technique can also be applied in case of a diffuse,
marked hypercellularity of the bone marrow (Fig. 10).
Diffuse or focal cell components of the normal, non-
neoplastic bone marrow, which appear iso- or hypointense
to intervertebral disks or skeletal muscle on plain T1-
weighted MR images do show a substantial signal loss on
USPIO-enhanced STIR images. If this signal loss is not
observed, a malignant infiltration is present (Fig. 10). On
the other hand, a USPIO-administration is not meaningful
in patients with a fatty marrow on T1-weighted MR
images, because there are obviously no cells present, which
could take up these particulate contrast agents. Thus,
USPIO may be applied in specific patients, where a
differentiation of hypercellular normal marrow and neo-
plastic infiltration is warranted.
New therapy regimens
Angiogenesis-inhibiting drugs, such as thalidomide, may
be useful for treating hematologic malignancies that
depend on neovascularization, and these agents were
recently added to some treatment regimens for patients
with advanced myeloma [74]. The anti-angiogenic therapy
is intended to stop cancer progression by suppressing the
tumor recruitment of new blood supply. As such, the anti-
Fig. 8 A patient with myeloma
at different stages of therapy.
a) After chemotherapy and irra-
diation, the bone marrow of the
pelvis and proximal femurs
shows a major fatty conversion
with small areas of hypointense,
cellular marrow of uncertain
significance on plain T1-
weighted MR images. b) After
high-dose chemotherapy and
GCSF treatment, several areas
of hypercellular, hypointense
marrow are seen in the marrow
of the pelvis and proximal
femurs. The lower row of im-
ages shows that these areas
appear bright on FS-T2-w im-
ages (b1), hypointense on plain
T1-w images (b2) and show a
marked enhancement on Gd-
enhanced T1-w scans (b3). A
follow up study, 3 months after
the study in (c), shows again a
fatty conversion of the bone
marrow. In retrospect, the
lesions in B were most likely
due to reconverted
hematopoietic marrow
754angiogenic drugs are generally tumorostatic, not cytotoxic.
Thus, a successful therapeutic inhibition of angiogenesis
can be expected to slow or stop tumor growth, but not to
cause tumor regression or disappearance. Accordingly, MR
imaging may show a persistent high bone marrow cellu-
larity under anti-angiogenic treatment. Signs of a response
to this treatment are rather a delayed, less steep and smaller
bone marrow enhancement after intravenous administra-
tion of small molecular Gd-chelates compared to pretreat-
ment studies.
New macromolecular contrast agents (MMCM) may
provide an earlier diagnosis of response or failure of anti-
angiogenic treatment than standard small molecular con-
trast agents. MMCM are more sensitive in the detection of
changes in vascular permeability than small molecular
contrast agents. And such changes in the permeability of
bone marrow sinus occurs earlier than changes in perfusion
and blood volume, typically assessed with small molecular
contrast agents. In animal models, MMCM-enhanced MRI
was able to define anti-VEGF effects of certain angiogen-
esis inhibitors as early as one day after initiation of therapy
[75, 76]. Future studies have to show, if these results can be
also obtained in patients and if so, they would be obviously
of high clinical significance for treatment monitoring and
management.
In clinical practice, anti-angiogenic therapy regimens
will almost certainly combine anti-angiogenic drugs with
cytotoxic drugs. The effect of such combined therapies on
the tumor accumulation and therapeutic effect of the
individual drugs are complex and currently investigated in
several experimental and clinical trials. Again, imaging
techniques are the only available tool to provide a non-
invasive and serial assessment of such combined therapy
regimens. Some angiogenesis inhibitors, such as anti-
VEGF antibody, decrease microvessel permeability and
thereby reduce tumoral delivery of large molecular cyto-
toxic drugs, but not small molecular cytotoxic drugs [76].
MRI assays of angiogenesis can monitor such anti-
angiogenesis therapy induced changes in tumor microvas-
cular structure and optimize the choice and timing
of cytotoxic drug administration. Other inhibitors of
angiogenesis, such as anti-angiogenic steroids (tetrahydro-
cortisol, cortisone acetate), cyclodextrin derivates 460
(cyclodextrin tetradecasulfate), and tetracycline derivates
Fig. 9 A 42-year-old patient
after recurrent chemotherapy
and GCSF treatment with re-
converted, hyperplastic hemato-
poietic marrow and multifocal
bone marrow infiltration by
lymphoma. Both hematopoietic
marrow and focal tumor
infiltration show a low signal
intensity on plain T1-weighted
images (a), as well as an
increased signal intensity on
plain STIR images (b); howev-
er, STIR images after iron oxide
administration (c) show a
marked signal decrease of the
hematopoietic marrow, whereas
focal tumors (arrows) do not
show any iron oxide uptake;
thus, the tumor-to-bone marrow
contrast increases substantially
(figure from [31])
755(minocycline), may increase tumor microvascular perme-
ability and thus potentiate certain cytotoxic therapies [77,
78]. In addition, inhibitors of angiogenesis have been
shown to effectively potentiate tumor irradiation effects
[79]. This possible synergy between these anti-angiogen-
esis drugs and cytotoxic drugs or irradiation, as a function
of apparent tumor microvascular hyperpermeability, can
also be interrogated with MMCM-enhanced MR imaging.
Stem cell transplantation
The most commonly used therapy for patients with
lymphoma is autologous stem cell transplantation. For
this, the patient receives a conditioning therapy, then his or
her own stem cells are collected by leukapheresis, the
patient subsequently receives a high-dose chemotherapy or
irradiation and his previously collected stem cells are
reinfused. With some types of lymphoma, an autologous
transplant may not be possible in case of persistent
malignant bone marrow infiltration. Even after purging
(treatment of the stem cells in the lab to kill or remove
lymphoma cells), reinfusion of some lymphoma cells with
the stem cell transplant is possible. It would, therefore, be
of high clinical significance to be able to differentiate
patients with still viable lymphoma cells in their bone
marrow at the time of leukapheresis from patients in true
complete remission.
In refractory diseases or in aplastic anemia, allogenic
marrow transplantation or chord cell transplantation are
also used. This much more aggressive procedure is initiated
by a conditioning high dose chemotherapy and/or total
body irradiation and subsequent reinfusion of allogenic
donor cells, i.e., stem cells from a matched sibling or
unrelated donor. Allogenic transplantation has limited
applications, because of the need for a matched donor.
Another drawback is that side effects of this treatment are
too severe for most people over 55 years old. After the
conditioning therapy for allogenic marrow transplantation,
the patients reach complete aplasia, are usually isolated on
a bone marrow transplantation unit and should only
undergo MR imaging for vital indications.
Only limited studies exist about the evaluation of bone
marrow with MR imaging in the setting of bone marrow
transplantation in patients with hematologic disorders.
Based on these data, the MR imaging characteristics of the
bone marrow after autologous or allogenic marrow trans-
plantation are apparently quite similar [80].
After the conditioning therapy and before bone marrow
transplantation, the bone marrow would be assumed to be
depleted of tumor cells. Ideally, a conversion from focal or
diffuse hypercellular marrow to normocellular or fatty
Fig. 10 A 57-year-old patient
with myeloma after chemother-
apy and GCSF treatment.
T1-weighted images before
(a) show a pathologic fracture of
Th 9 (arrow) and a diffuse
hypointense signal intensity of
the bone marrow in all verte-
brae, compatible with a high
bone marrow cellularity. Unen-
hanced STIR images (b) show a
diffuse hyperintense bone mar-
row, also compatible with high
bone marrow cellularity. After
iron oxide infusion, the hyper-
cellular bone marrow shows
only minimal changes in signal
intensity on STIR images (c),
indicative of a diffuse tumor
infiltration. Iliac crest biopsy
revealed 80% tumor cells in the
bone marrow (figure from [31])
756marrow would be expected to occur after the induction
high-dose chemotherapy. However, MR studies in patients
before bone marrow transplantation showed that some
patients have persistent focal lesions. Metz et al. described
residual focal bone marrow lesions in patients with
lymphomas right before leukapheresis [17]. Negendak
and Soulen found that patients with residual lesions on MR
before bone marrow transplantation had a significantly
shorter median time until relapse compared to patients who
did not show any residual bone marrow disease on MR
images [81]. By contrast, Lecouvet et al. reported that
patients with an apparently normal marrow and patients
with a persistent pathologic bone marrow right before
autologous or allogenic transplantation did not show
differences in survival [80]. One reason for this difference
in observation may be the limitation of the MR imaging
technique to detect and differentiate viable and non-viable
tumor cells. Some patients with a “clean” bone marrow
may have residual microscopic active tumor cells while
macroscopic residual lesions on MR imaging in other
patients may or may not beviable.In ouropinion, it would
be highly significant to investigate MR imaging criteria
(e.g., diffusion weighted MR, dynamic MR, new contrast
agents, spectroscopy) for the differentiation of such
persistent focal bone marrow lesions that may or may
not develop to recurrent disease after stem cell transplan-
tation.
After bone marrow transplantation, the evolution of
distinct MR signal patterns of the bone marrow has been
described [82, 83]. During the first post-transplantation
days, the bone marrow shows a decline in signal intensity
on T1-weighted images and an increased signal intensity
on T2-weighted images, probably due to a treatment-
induced edema. Within 3 months from bone marrow
transplantation, a characteristic band pattern appears on
T1-weighted MR images of the spine. This band pattern
consists of a peripheral T1-hypointense zone and a central
T1-hyperintense zone. At histologic examination, the
peripheral zone corresponded to repopulating hematopoi-
etic marrow and the central zone to marrow fat. This “band
pattern” may be seen for several months [82, 83].
Subsequently, the band pattern gradually evolves into a
homogeneous appearance of the marrow after successful
bone marrow transplantation. On late post-transplant MR
studies, years after bone marrow transplantation, the bone
marrow shows the fatty conversion of adult marrow. The
signal intensity of the post-transplant bone marrow on T1-
weighted MR images is usually increased compared to age-
matched controls [84].
In some patients, residual marrow abnormalities may be
observed on MR images after bone marrow transplantation
and the administration of high-dose myeloablative chemo-
therapy, in the same way that they may occur after
conventional chemotherapy and conditioning chemothera-
py regimens, described above (Fig. 11). For example,
sharply defined focal low signal intensity areas of bone
marrow on T1-weighted images have been reported in
patients who are in complete remission after transplantation
[85]. Patients with these abnormalities did not have a
poorer outcome than those with normal post-transplanta-
tion MR imaging findings [80]. These data show that there
is clearly a need for the MR imaging technique to add some
functional information to the anatomical data, e.g., by
adding spectroscopy, perfusion studies or markers for
tumor cell proliferation.
Of note, iron overload commonly accompanies bone
marrow transplantation and may result in a diffusely
decreased signal intensity of the liver (reported in 77% of
pediatric cases after bone marrow transplantation), spleen
(46%) and bone marrow (38.5%) on T2-weighted and
Fig. 11 Patient with malignant lymphoma after TBI and bone
marrow transplantation: Plain T1-w MR image (center) shows
residual hypointense bone marrow lesions in the pelvis and proximal
femur. Some of these lesions may be residual marrow abnormalities
of uncertain significance. Other lesions, such as the serpiginous
lesions in both proximal femurs represent therapy-induced bone
infarcts. These lesions show a corresponding serpiginous hyper-
intense area on STIR images (left) and a minor, serpiginous
enhancement on Gd-enhanced T1-w scans (right)
757STIR MR images (Fig. 12). The degree of hepatic iron
overload correlated significantly and splenic iron overload
correlated weakly with the number of blood transfusions
[86].
TBI can cause irradiation induced signal changes and
complications, described above (Fig. 11). Long-term
complications of TBI, applied as part of the conditioning
regimen for a bone marrow transplantation, are the
development of osteochondromas or sarcomas.
In summary, MR imaging can be a useful tool to aid in
the treatment monitoring of patients with hematologic
malignancies by monitoring treatment response, detecting
treatment complications, differentiating normal and neo-
plastic hypercellular marrow and by diagnosing residual or
recurrent tumor deposits. In order to achieve clinical
significance and cost-effectiveness, the MR imaging
technique should be clearly tailored to specific patients
and the specific questions described in detail above. New
MR imaging techniques may serve to depict those
molecular pathways and regulatory events that control
blood vessel growth and proliferation. Non-invasive
monitoring of anti-angiogenic therapies has found success
by defining tumor microvascular and metabolic changes,
while treatment-related changes in bone marrow morphol-
ogy tend to occur rather late and are non-specific. Already
established in many institutions, future developments will
almost certainly include “fusion” or “hybrid” imaging
methods, such as PET-CT and PET-MR in the treatment
monitoring of patients with malignant lymphomas.
Fig. 12 A patient with myeloma after bone marrow transplantation:
The bone marrow of the lumbar spine shows a diffuse hypointense
signal intensity on both plain T1-weighted (left) and fat-saturated
T2-weighted (right) MR images
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